Interesting article, thanks for posting.
I'm not sure I would classify all the drugs listed as competitors to MPL though:
ABBVCLS-7262 may be, I am not across it enough to say for sure either way. It is also targeting TPD43 but the mechanism appears to be different so could be complementary.
I would be interested to hear from anyone who has a better grasp of how this drug compares to MPL?
AP-01 appears to be targeting the SOD1 variant (MPL is not, Patients at risk of or known to carry a SOD1 mutation or VCP mutation were excluded from the MPL trial)
CNMAU-8: I believe this has a different target (ie not autophagy) so may be complementary - I would be keen to hear more from anyone who has a good grasp of this?
RAPA-501 This is an open-label, non-randomized, multi-center intermediate size expanded access clinical trial of single-agent RAPA-501 cells in patients with high-risk ALS who are not eligible for other ALS clinical trials.
- Forums
- ASX - By Stock
- PharmAust media thread
Interesting article, thanks for posting. I'm not sure I would...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
|
|||||
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $85.12M |
Open | High | Low | Value | Volume |
18.0¢ | 18.0¢ | 17.0¢ | $141.2K | 801.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 537419 | 17.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.0¢ | 140000 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 537419 | 0.170 |
5 | 157060 | 0.165 |
9 | 476304 | 0.160 |
6 | 336734 | 0.155 |
8 | 225333 | 0.150 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 140000 | 3 |
0.185 | 427553 | 5 |
0.190 | 720215 | 6 |
0.195 | 752882 | 12 |
0.200 | 297726 | 10 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |